{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:28:21Z","timestamp":1759940901562},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T00:00:00Z","timestamp":1545955200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Research Council of New Zealand"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.1093\/rheumatology\/key423","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T02:25:24Z","timestamp":1543803924000},"page":"547-548","source":"Crossref","is-referenced-by-count":8,"title":["No association between <i>ATP-binding cassette transporter G2<\/i> rs2231142 (Q141K) and urate-lowering response to febuxostat"],"prefix":"10.1093","volume":"58","author":[{"given":"Lisa K","family":"Stamp","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Otago, Christchurch, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Topless","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, University of Otago, Dunedin, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey N","family":"Miner","sequence":"additional","affiliation":[{"name":"General Atomics Court, Viscentio Bio, San Diego, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Merriman","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, University of Otago, Dunedin, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,12,27]]},"reference":[{"key":"key\n\t\t\t\t2019022006304327400_key423-B1","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology Guidelines for the Management of Gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"key\n\t\t\t\t2019022006304327400_key423-B2","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/cpt.89","article-title":"Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response","volume":"97","author":"Wen","year":"2015","journal-title":"Clin Pharm Ther"},{"key":"key\n\t\t\t\t2019022006304327400_key423-B3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/tpj.2015.101","article-title":"ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout","volume":"17","author":"Roberts","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"key\n\t\t\t\t2019022006304327400_key423-B4","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/rheumatology\/kex467","article-title":"Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis","volume":"57","author":"Wallace","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"key\n\t\t\t\t2019022006304327400_key423-B5","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/ncomms1756","article-title":"Decreased extra-renal urate excretion is a common cause of hyperuricemia","volume":"3","author":"Ichida","year":"2012","journal-title":"Nat Commun"},{"key":"key\n\t\t\t\t2019022006304327400_key423-B6","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3389\/fphar.2016.00518","article-title":"Identification of febuxostat as a new strong ABCG2 inhibitor: potential applications and risks in clinical situations","volume":"7","author":"Miyata","year":"2016","journal-title":"Front Pharmacol"},{"key":"key\n\t\t\t\t2019022006304327400_key423-B7","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/art.40159","article-title":"Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022006304327400_key423-B8","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/ng1847","article-title":"Principal components analysis corrects for stratification in genome-wide association studies","volume":"38","author":"Price","year":"2006","journal-title":"Nat Genet"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/58\/3\/547\/27900966\/key423.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T15:11:21Z","timestamp":1550675481000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/58\/3\/547\/5265273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,27]]},"references-count":8,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,12,27]]},"published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key423","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2018,12,27]]}}}